Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alnuctamab vs Standard of Care in RRMM
NCT06232707Phase 3Withdrawn
- Sponsor
- Celgene Corporation
- Start
- May 2024
- Primary completion
- Nov 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Alnuctamab with Standard of Care (2 arms). Primary endpoint: Progression-free Survival up to 5 years. Planned start May 2024; status: withdrawn.
02
Drugs
alnuctamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06232707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232707.